engasertib

News

A trial of Vaderis' AKT inhibitor engasertib finds it could be the first effective treatment for rare disease hereditary haemorrhagic telangiectasia.

News

Germany's government is reportedly scrapping plans to introduce a controversial system of variable rebates on medicines.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.